Vertex Pharmaceuticals Incorporated (VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019. Mr. Wagner will report directly to Vertex Chairman, President and Chief Executive Officer Jeffrey Leiden, M.D., Ph.D., and oversee the finance, internal audit, investor relations, and global security and facilities functions. Mr. Wagner joins Vertex with deep corporate finance and health care experience, including more than a decade in public and private company CFO roles.
“Charlie is a proven finance leader with extensive experience working in a public company setting, and he will be a tremendous asset to Vertex and our strong team,” said Dr. Leiden. “As we continue to build Vertex for the future, Charlie’s strategic mindset, operational expertise, and broad leadership experience will prove invaluable. I’d like to thank our interim CFO, Paul Silva, for his contributions and leadership. Paul will continue in his role as Corporate Controller upon Charlie’s arrival.”
Mr. Wagner joins Vertex from Ortho Clinical Diagnostics, Inc. – a Carlyle Group portfolio company, where he served as CFO and EVP, Finance. In this role, he had leadership responsibilities for all aspects of finance, accounting, tax, treasury, global information systems, lender relations, and acquisitions and divestitures, as well as shared responsibility for several enterprise-wide projects. Prior to this, Mr. Wagner served as CFO for publicly- traded Bruker Corporation, Progress Software Corporation and Millipore Corporation. In addition to his corporate finance roles, Mr. Wagner served as an advisor at Bain & Company and Coopers & Lybrand. He received his BS in accounting from Boston College and his MBA from Harvard Business School.
“I am excited to be joining Vertex at such a dynamic time as the company continues to deliver more transformational medicines for cystic fibrosis patients and accelerates its pipeline of innovative and novel life-changing treatments for patients with other serious diseases,” said Mr. Wagner. “I look forward to working with Vertex’s senior leadership team and employees to help the company continue to drive value through its remarkable innovation.”
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for nine years in a row.
For additional information and the latest updates from the company, please visit www.vrtx.com.
Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements in the second and fourth paragraphs of this press release. While Vertex believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.